Degradation of NSD3: What to Myc of it all?

Adam I Green; George M Burslem

doi:10.1016/j.chembiol.2022.03.005

Degradation of NSD3: What to Myc of it all?

Cell Chem Biol. 2022 Mar 17;29(3):356-357. doi: 10.1016/j.chembiol.2022.03.005.

Authors

Adam I Green¹, George M Burslem²

Affiliations

¹ Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
² Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Department of Cancer Biology Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Penn Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: george.burslem@pennmedicine.upenn.edu.

PMID: 35303440
DOI: 10.1016/j.chembiol.2022.03.005

Abstract

Preventing uncontrolled gene expression is a powerful therapeutic strategy for the treatment of cancers. In this issue of Cell Chemical Biology, Xu et al. (2022) describe a series of proteolysis targeting chimeras that induce the degradation of NSD3 and suppress cMyc-related oncogene transcription in a model of acute myeloid leukemia.

Publication types

Comment

MeSH terms

Humans
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / metabolism
Proteolysis